GLGS GLYCOGENESYS Volumen sind einfach unglaublich....
Geh klein mit...
chart.bigcharts.com/bc3/quickchart/...71&mocktick=1&rand=7845" style="max-width:560px" >
United States Patent and Trademark Office Grants GlycoGenesys, Inc. Key Patent for Expanding Use of Cancer Drug Candidate
Wednesday February 18, 8:45 am ET
Patent Protects Use of GCS-100 and Other Galectin Binding Carbohydrate Compounds in Combination With Chemotherapy or Surgery
BOSTON--(BUSINESS WIRE)--Feb. 18, 2004-- GlycoGenesys, Inc., (Nasdaq: GLGS - News), a biotechnology company developing carbohydrate-based drugs, today announced that the U.S. Patent and Trademark Office issued the Company a U.S. Patent No. 6,680,306 "Method for Enhancing the Effectiveness of Cancer Therapies" covering the use of GCS-100® and other carbohydrates that bind to galectins prior to or in combination with chemotherapy or surgery for the treatment of cancer.
ADVERTISEMENT
Patent's Potential Practical Applications
In June 2003, at an American Society of Clinical Oncology (ASCO) Industry Sponsored Satellite Symposium, Dr. Finbarr Cotter, the editor of The British Journal of Haematology and a professor at St. Bartholomew's and The Royal School of Medicine, London, reported preclinical data illustrating the potential synergy of GCS-100 in combination with Etoposide. When GCS-100 was administered in combination with Etoposide in vitro, it improved Etoposide's anti-cancer effect at substantially lower doses than typically administered in a chemotherapy resistant human lymphoma cell line. To date, GCS-100 has been developed as a monotherapy for potential treatment of multiple solid tumor cancers. The combination patent greatly expands GCS-100's potential clinical applications and market if it were to gain future governmental regulatory approvals.
Based on this and other pre-clinical research, in addition to planned monotherapy trials, the Company plans to begin clinical trials of GCS-100 in combination with approved chemotherapies, in a variety of cancer indications later this year.
Management's Comments
"Intellectual Property is the corner stone of our glycobiology driven cancer drug development and discovery efforts. The granting of this important U.S. Patent significantly strengthens GlycoGenesys' intellectual property position. We have secured patent protection for using GCS-100 and, importantly, other galectin binding carbohydrate compounds in combination with chemotherapies or surgery," stated Bradley J Carver, CEO and President of GlycoGenesys, Inc.
Developing Intellectual Property Portfolio
Additional preclinical studies involving GCS-100 are continuing at the labs of well-known cancer researchers. These studies are designed to both evaluate potential synergistic effects of GCS-100 when combined with additional widely- used chemotherapeutic agents, as well as, further enhance the understanding of the mechanistic activities of GCS-100 as a monotherapy in bloodborne and solid tumor cancers. The Company believes this work will enable its continued enhancement of its carbohydrate-based intellectual property portfolio.
In addition to the patent announced today, the Company has additional U.S. and international patent applications on file relating to the use of GCS-100 and similar carbohydrates in combination with other therapies to treat cancer and diseases outside of the field of oncology.
GlycoGenesys, Inc.
GlycoGenesys is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently completed a Phase I dose escalation trial of GCS-100 up to 80 mg/m2 at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
Safe Harbor Statement
Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including, but not limited to, risks of product development (such as failure to demonstrate efficacy or safety), risk related to FDA and other regulatory procedures, market acceptance risks, the impact of competitive products and pricing, the results of current and future licensing, joint ventures and other collaborative relationships, the results of financing efforts, developments regarding intellectual property rights and litigation, and other risks identified in the Company's Securities and Exchange Commission filings. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
--------------------------------------------------
Contact:
GlycoGenesys
John W. Burns, 617-422-0674
Senior Vice President and CFO
or
Rick Pierce, 617-422-0674
VP of Business Development
Geh klein mit...
United States Patent and Trademark Office Grants GlycoGenesys, Inc. Key Patent for Expanding Use of Cancer Drug Candidate
Wednesday February 18, 8:45 am ET
Patent Protects Use of GCS-100 and Other Galectin Binding Carbohydrate Compounds in Combination With Chemotherapy or Surgery
BOSTON--(BUSINESS WIRE)--Feb. 18, 2004-- GlycoGenesys, Inc., (Nasdaq: GLGS - News), a biotechnology company developing carbohydrate-based drugs, today announced that the U.S. Patent and Trademark Office issued the Company a U.S. Patent No. 6,680,306 "Method for Enhancing the Effectiveness of Cancer Therapies" covering the use of GCS-100® and other carbohydrates that bind to galectins prior to or in combination with chemotherapy or surgery for the treatment of cancer.
ADVERTISEMENT
Patent's Potential Practical Applications
In June 2003, at an American Society of Clinical Oncology (ASCO) Industry Sponsored Satellite Symposium, Dr. Finbarr Cotter, the editor of The British Journal of Haematology and a professor at St. Bartholomew's and The Royal School of Medicine, London, reported preclinical data illustrating the potential synergy of GCS-100 in combination with Etoposide. When GCS-100 was administered in combination with Etoposide in vitro, it improved Etoposide's anti-cancer effect at substantially lower doses than typically administered in a chemotherapy resistant human lymphoma cell line. To date, GCS-100 has been developed as a monotherapy for potential treatment of multiple solid tumor cancers. The combination patent greatly expands GCS-100's potential clinical applications and market if it were to gain future governmental regulatory approvals.
Based on this and other pre-clinical research, in addition to planned monotherapy trials, the Company plans to begin clinical trials of GCS-100 in combination with approved chemotherapies, in a variety of cancer indications later this year.
Management's Comments
"Intellectual Property is the corner stone of our glycobiology driven cancer drug development and discovery efforts. The granting of this important U.S. Patent significantly strengthens GlycoGenesys' intellectual property position. We have secured patent protection for using GCS-100 and, importantly, other galectin binding carbohydrate compounds in combination with chemotherapies or surgery," stated Bradley J Carver, CEO and President of GlycoGenesys, Inc.
Developing Intellectual Property Portfolio
Additional preclinical studies involving GCS-100 are continuing at the labs of well-known cancer researchers. These studies are designed to both evaluate potential synergistic effects of GCS-100 when combined with additional widely- used chemotherapeutic agents, as well as, further enhance the understanding of the mechanistic activities of GCS-100 as a monotherapy in bloodborne and solid tumor cancers. The Company believes this work will enable its continued enhancement of its carbohydrate-based intellectual property portfolio.
In addition to the patent announced today, the Company has additional U.S. and international patent applications on file relating to the use of GCS-100 and similar carbohydrates in combination with other therapies to treat cancer and diseases outside of the field of oncology.
GlycoGenesys, Inc.
GlycoGenesys is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently completed a Phase I dose escalation trial of GCS-100 up to 80 mg/m2 at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
Safe Harbor Statement
Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including, but not limited to, risks of product development (such as failure to demonstrate efficacy or safety), risk related to FDA and other regulatory procedures, market acceptance risks, the impact of competitive products and pricing, the results of current and future licensing, joint ventures and other collaborative relationships, the results of financing efforts, developments regarding intellectual property rights and litigation, and other risks identified in the Company's Securities and Exchange Commission filings. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
--------------------------------------------------
Contact:
GlycoGenesys
John W. Burns, 617-422-0674
Senior Vice President and CFO
or
Rick Pierce, 617-422-0674
VP of Business Development
